SNY - Pfizer Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants | Benzinga
As the respiratory virus season kicks off, healthcare providers are racing against time to offer Pfizer Inc's (NYSE: PFE) vaccine, Abrysvo, to pregnant patients and Sanofi SA's (NASDAQ: SNY) monoclonal antibody, Beyfortus, to protect against respiratory syncytial virus (RSV) complications in infants.
However, several challenges loom, including insurance coverage and the substantial cost of these treatments, which raise concerns among providers about stocking up without guaranteed payment.
While often resembling a common cold in adults, RSV poses a significant threat to newborns, seniors, and adults with chronic medical ...